Circulating growth arrest-specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients

Miao Pei Chen, Chien Wen Chen, Jin Shuen Chen, Hung Chung Mao, Chu Lin Chou

Research output: Contribution to journalArticle

3 Citations (Scopus)


Growth arrest-specific protein 6 (Gas6) works synergistically with erythropoietin (EPO) to increase the proliferation and maturation of erythroblasts. However, the role of Gas 6 levels on EPO resistance in hemodialysis (HD) patients remains unclear. Therefore, the objective of this study was the first to examine the correlation between plasma Gas6 levels and EPO resistance in HD patients. We enrolled 134 HD patients and 85 healthy individuals. The HD patients were divided into 2 groups: 98 non-EPO-resistant patients and 36 EPO-resistant patients. Plasma levels of Gas6, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and albumin were quantified. Compared with non-EPO-resistant patients, EPO-resistant patients had elevated plasma concentrations of Gas6 (15.4 ± 3.3 vs. 13.7 ± 3.2 ng/mL, P = 0.006), IL-6 (3.1 ± 3.1 vs. 2.1 ± 1.5 pg/mL, P = 0.009), and hs-CRP (12.7 ± 25.2 vs. 4.5 ± 5.5 mg/L, P = 0.002). In EPO-resistant HD patients, plasma Gas6 levels were negatively correlated with albumin levels (r = −0.388, P < 0.021). Elevated Gas6 levels are associated with EPO resistance in HD patients. Also, EPO resistance is related to inflammation and malnutrition. Thus, circulating Gas6 levels could be used as the potential marker in HD patients with EPO resistance.

Original languageEnglish
Article number29
Pages (from-to)1-6
Number of pages6
Issue number1
Publication statusPublished - Dec 1 2016
Externally publishedYes



  • Erythropoietin
  • Growth arrest-specific protein 6
  • Hemodialysis
  • High-sensitivity C-reactive protein
  • Interleukin 6

ASJC Scopus subject areas

  • General

Cite this